PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform
Others

PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
CompanyDrug

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy

CompanyDrug

Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China

Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
CompanyDrug

Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
CompanyDeals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

CompanyDeals

uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO

CompanyDeals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

CompanyDeals

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

CompanyDrug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

CompanyDeals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

CompanyDrug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

CompanyDrug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist